BEIJING, June 5, 2025 /PRNewswire/ — Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and peptide therapeutics, held in San Diego from May 19 to 22. As a repeat exhibitor, Tsingke highlighted its integrated “The Great Gene Factory” model, offering precision synthesis solutions from early discovery to large-scale manufacturing.
During the exhibition, Tsingke showcased its core offerings including:
- End-to-End synthesis tools, such as the Syn-HCY Series (12P/192P/768B), delivering high-throughput oligo production for CRISPR, IVD, and research needs
- GMP production system, featuring the Syn-HL12 synthesizer capable of 200 nmol to 12 mmol scale, equipped with real-time monitoring for UV, pH, and conductivity
- Application coverage across ASO/siRNA therapeutics, gene editing, mRNA vaccine templates, and diagnostic probes
- Over 300 chemical modifications and a robust raw material supply chain supporting batch-to-batch consistency
Visitors were particularly impressed by Tsingke’s automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company’s ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners.
Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis.
For inquiries or collaboration, please contact us at [email protected]
Visit: www.tsingke.com
